Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00961207 · ClinicalTrials.gov registry record · Phase 4
Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients
A Phase 4 study, sponsored by Cook County Health.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT00961207 is a Phase 4 study that was terminated before completion, run by Cook County Health. The registered enrollment target is 2 participants.
The verdict
NCT00961207, a Phase 4 study, was terminated before completion, sponsored by Cook County Health.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
Study Hypothesis: Reduction in albuminuria has been shown to decrease progression of diabetic nephropathy. In diabetic nephropathy patients treated with maximal antihypertensive doses with dual RAAS blockade (total daily dose valsartan 320 mg and either enalapril 40 mg or benazepril 40 mg daily, or losartan 100mg), persistent albuminuria reflects further additional RAAS activation. Microvascular renal disease due to increased RAAS activation may be more effectively treated with triple blockade by the addition of a direct renin inhibitor (DRI) Aliskiren.
Interventions
- DRUG Aliskiren
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2009-08 |
| Est. Completion | 2012-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00961207
The ClinicalTrials.gov registry entry for NCT00961207 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cook County Health, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aliskiren is the first listed.
NCT00961207 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00961207 about?
NCT00961207 is a clinical study titled "Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients". Study Hypothesis: Reduction in albuminuria has been shown to decrease progression of diabetic nephropathy. In diabetic nephropathy patients treated with maximal antihypertensive doses with dual RAAS blockade (total daily dose valsartan 320 mg and either enalapril 40 mg or benazepril 40 mg daily,...
What is the current status of trial NCT00961207?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2009-08. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00961207?
The interventions under investigation include: Aliskiren (DRUG).
Who is sponsoring clinical trial NCT00961207?
This trial is sponsored by Cook County Health, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.